PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
The standard of care imaging of prostate cancer metastases recommended by the National
Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be
suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen
(PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of
clinically significant metastases in patients with prostate cancer.